Jacob Y Shin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7927116/publications.pdf

Version: 2024-02-01

623734 501196 1,780 28 14 citations g-index h-index papers

28 28 28 2424 docs citations times ranked citing authors all docs

28

#	Article	IF	CITATIONS
1	Clinical outcomes of dose-escalated hypofractionated external beam radiotherapy (5 Gy x 5 fractions) for spine metastasis. Advances in Radiation Oncology, 2022, 7, 100906.	1.2	1
2	Association of prior radiation dose to the cardiopulmonary system with COVID-19 outcomes in patients with cancer. Radiotherapy and Oncology, 2021, 161, 115-117.	0.6	2
3	The influence of insurance status on treatment and outcomes in oral cavity cancer: an analysis on 46,373 patients. International Journal of Oral and Maxillofacial Surgery, 2018, 47, 1250-1257.	1.5	28
4	Locoregionally advanced oral cavity cancer: A propensityâ€score matched analysis on overall survival with emphasis on the impact of adjuvant radiotherapy. Head and Neck, 2018, 40, 1934-1946.	2.0	3
5	Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer. Lung, 2018, 196, 351-358.	3.3	21
6	Racial disparities in anaplastic oligodendroglioma: An analysis on 1643 patients. Journal of Clinical Neuroscience, 2017, 37, 34-39.	1.5	10
7	External Validation of the New International Association for the Study of Lung Cancer Tumor, Node, and Metastasis 8th Edition Staging System and Updated T Descriptors in Determining Prognosis for Patients With Non–Small Cell Lung Cancer Patients With N3 Disease. Clinical Lung Cancer, 2017, 18, e481-e489.	2.6	7
8	Influence of insurance status and income in anaplastic astrocytoma: an analysis of 4325 patients. Journal of Neuro-Oncology, 2017, 132, 89-98.	2.9	8
9	Gliosarcoma in septuagenarians and octogenarians: What is the impact of adjuvant chemoradiation?. Journal of Clinical Neuroscience, 2017, 45, 77-82.	1.5	9
10	Association of Insurance and Community-Level Socioeconomic Status With Treatment and Outcome of Squamous Cell Carcinoma of the Pharynx. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 899.	2.2	35
11	Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy. Journal of Neuro-Oncology, 2016, 129, 557-565.	2.9	12
12	Utilization and impact of adjuvant therapy in anaplastic oligodendroglioma: an analysis on 1692 patients. Journal of Neuro-Oncology, 2016, 129, 567-575.	2.9	7
13	Optimizing efficiency and safety in a radiation oncology department through the use of ARIA 11 Visual Care Path. Practical Radiation Oncology, 2015, 5, 295-303.	2.1	10
14	Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. Gynecologic Oncology, 2015, 136, 491-497.	1.4	58
15	The Impact of Race in Male Breast Cancer Treatment and Outcome in the United States: A Population-Based Analysis of 4,279 Patients. International Journal of Breast Cancer, 2014, 2014, 1-14.	1.2	14
16	Factors associated with publication of plenary presentations at the Society of Gynecologic Oncologists annual meeting. Gynecologic Oncology, 2013, 128, 128-131.	1.4	7
17	Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States. Journal of Surgical Oncology, 2008, 97, 103-107.	1.7	82
18	The influence of conservative surgical practices for malignant ovarian germ cell tumors. Journal of Surgical Oncology, 2008, 98, 111-116.	1.7	79

#	Article	IF	CITATIONS
19	Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas. Cancer, 2008, 112, 820-830.	4.1	304
20	Factors associated with the suboptimal treatment of women less than 55Âyears of age with early-stage ovarian cancer. Gynecologic Oncology, 2008, 108, 95-99.	1.4	14
21	Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecologic Oncology, 2008, 109, 370-376.	1.4	359
22	Analysis of Phase II Studies on Targeted Agents and Subsequent Phase III Trials: What Are the Predictors for Success?. Journal of Clinical Oncology, 2008, 26, 1511-1518.	1.6	58
23	Vulvar Melanoma. Obstetrics and Gynecology, 2007, 110, 296-301.	2.4	125
24	Influence of the Gynecologic Oncologist on the Survival of Ovarian Cancer Patients. Obstetrics and Gynecology, 2007, 109, 1342-1350.	2.4	123
25	Adjuvant Radiotherapy in Incompletely Staged IC and II Endometrioid Uterine Cancer. Obstetrics and Gynecology, 2007, 110, 1237-1243.	2.4	11
26	Lymphadenectomy in endometrioid uterine cancer staging. Cancer, 2007, 109, 2454-2460.	4.1	85
27	Prognostic factors responsible for survival in sex cord stromal tumors of the ovary—An analysis of 376 women. Gynecologic Oncology, 2007, 104, 396-400.	1.4	155
28	The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecologic Oncology, 2007, 106, 282-288.	1.4	153